Eli Lilly, Bristol-Myers Squibb, GSK, Fleming Initiative, Johnson & Johnson, Sarah Cannon Research Institute, Pfizer, Sanofi, CHMP, AbbVie
Industry News

Bristol Myers Squibb announces early participation results
BMS update on phase 3 Librexia ACS trial

Sarah Cannon Research Institute and Bristol Myers Squibb announce expansion of collaboration to accelerate patient enrollment and widen access to innovative cancer research
Upcoming Webinars